(SIX/SFZN) Siegfried and BASF concluded the implementation of the agreements on 30 September 2015. Siegfried has thereby acquired BASF’s pharmaceutical supply business and the corresponding three sites in Evionnaz (CH), Saint-Vulbas (FR) and Minden (DE). The three sites with over 800 employees reported total sales for 2014 of approximately CHF 280 million. The debt-free price of acquisition amounts to approximately EUR 270 million.
Similar to Siegfried, the BASF business unit concerned supplies the worldwide pharmaceutical industry and produces active pharmaceutical ingredients and intermediate products and, therefore, ideally complements Siegfried. The combination of Siegfried and BASF’s pharmaceutical supply business represents an attractive base for sustained profitable growth.
Siegfried CEO Rudolf Hanko: "Through this acquisition, Siegfried will reach the critical size to play a leading role in the supplier market as a recognized partner for the pharmaceutical industry. This acquisition demonstrates the growth potential for the Siegfried Group."
Integration to be completed by the end of 2016
This acquisition represents the final step in Siegfried’s targeted acquisition policy implemented in the last five years. In terms of this policy, Siegfried previously acquired California-based AMP and Hameln Pharma in Hameln. Siegfried also commissioned a production plant in Nantong, in one of China’s most modern chemical industrial parks.
With total sales of approximately CHF 600 million and EBITDA of approximately CHF 100 million (pro forma combined 2014 figures), Siegfried has now reached the necessary size to remain a comprehensive and leading supplier in the ongoing consolidation process. The acquired BASF business units will contribute to the result starting from the fourth quarter 2015. The Siegfried Group now employs a total workforce of over 2,300 employees at nine sites on three continents.
For further information:
|Financial Analysts: |
Michael Huesler, CFO
Siegfried Holding AG
Untere Brühlstrasse 4
Tel. +41 (0)62 746 11 11
Fax +41 (0)62 746 11 03
The Siegfried Group is active worldwide in the field of Life Sciences with production facilities located in Switzerland, Germany, China, Malta and in the USA. At the end of 2014, Siegfried reported annual sales of CHF 315 million and employs at the time being approximately 1400 employees. Siegfried Holding AG is listed on the Swiss Exchange (SIX: SFZN).
Siegfried is active in both the primary and secondary production of drugs. The company develops and manufactures active pharmaceutical ingredients for the research-based pharmaceutical industry as well as the corresponding intermediate steps and controlled substances, and provides development and production services for drugs in finished dosage forms including sterile filling.
This communication contains certain forward-looking statements. Such statements are based on assumptions and expectations which could prove incorrect. They should be treated with appropriate caution because they naturally involve known and unknown risks, uncertainties and other factors which could mean that the actual results, financial situation, development or performance of Siegfried Holding AG or the Siegfried Group are materially different from those explicitly or implicitly assumed in these statements.
The purpose of this document is to inform investors in Siegfried Holding AG and the public about the closing of the acquisition of significant elements of the pharmaceutical supply business of BASF and connected three production sites. This document does not constitute an offer or a solicitation to exchange, buy or subscribe to securities in any jurisdiction, nor does it constitute an offering prospectus as defined by Art. 652a or Art. 1156 of the Swiss Code of Obligations or a listing prospectus as defined by the listing rules of the SIX Swiss Exchange.
This document is available in German, English and French. The German version is binding.